Rethinking composite end points in clinical trials: insights from patients and trialists. - Wikidata - wikimedia - TriplyDB

Rethinking composite end points in clinical trials: insights from patients and trialists.

Rethinking composite end points in clinical trials: insights from patients and trialists.

http://www.wikidata.org/entity/Q34766146

about

Stroke and anticoagulation in heart failure without atrial fibrillation: from risk to opportunity.Predictable and SuStainable Implementation of National Cardiovascular Registries (PASSION) infrastructure: A think tank report from Medical Device Epidemiological Network Initiative (MDEpiNet)Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research.Getting (Along) With the Guidelines: Reconciling Patient Autonomy and Quality Improvement Through Shared Decision Making.Clinical Relevance of Rehospitalizations for Unstable Angina and Unplanned Revascularization Following Acute Myocardial Infarction Weighted win loss approach for analyzing prioritized outcomes.Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.Global Outcome in Patients With Left Ventricular Assist Devices.Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization.Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure.Blood pressure dynamics during exercise rehabilitation in heart failure patients.The effect of different combinations of vascular, dependency and cognitive endpoints on the sample size required to detect a treatment effect in trials of treatments to improve outcome after lacunar and non-lacunar ischaemic stroke Understanding Neurologic Complications Following TAVR

P2860

Q35554746-BFFE0F03-C13C-4A98-A724-C694CD760FFD Q36407121-2315DA51-2FDC-4ED7-83DA-274E6C4355A3 Q36837610-8E220D92-7E45-4447-A638-2B4FFB1B26F9 Q37036719-AAA30AC1-C4DE-4DCB-B5E1-50BA8AE04FE4 Q37240339-ECEC9000-C694-4B7E-A5A8-32CE4B58C90D Q38875938-5084900F-ECDE-4D61-A0C4-A74B956221C1 Q39628955-F9AB75D7-97DD-4EF0-9242-D4F02D193270 Q40349834-35616AB2-6D3A-4031-90C2-2281D2511961 Q47634232-D34FA63C-7B06-4F09-A5B5-205971D22CBB Q47771118-097EDA8D-9C9E-4564-9F40-C6D61A9A2B60 Q47834948-8869914E-B96B-4BD0-8EB9-1D729A72F97E Q47867529-B1B193F4-C585-4853-A58A-1F0FE851D80F Q57305057-B7B063B5-274F-4262-8960-BB7DDB0A6089 Q57646814-D36CB43A-8A91-4A77-8BA0-229AABB7CE83

P2860

Rethinking composite end points in clinical trials: insights from patients and trialists.

http://www.wikidata.org/entity/Q34766146

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Rethinking composite end points in clinical trials: insights from patients and trialists.

@ast

Rethinking composite end points in clinical trials: insights from patients and trialists.

@en

Rethinking composite end points in clinical trials: insights from patients and trialists.

@nl

type

label

Rethinking composite end points in clinical trials: insights from patients and trialists.

@ast

Rethinking composite end points in clinical trials: insights from patients and trialists.

@en

Rethinking composite end points in clinical trials: insights from patients and trialists.

@nl

prefLabel

Rethinking composite end points in clinical trials: insights from patients and trialists.

@ast

Rethinking composite end points in clinical trials: insights from patients and trialists.

@en

Rethinking composite end points in clinical trials: insights from patients and trialists.

@nl

P1433

Q34766146-F570F924-49FD-44FD-9B15-737F767962F1

P1476

Q34766146-51B8E017-2A35-4743-8E02-AA90757989E0

P2093

Q34766146-1D8E2DD9-8D30-4375-86FD-F7A1E2CA363C

Q34766146-1FFE9E17-E273-40DF-A7A9-7793BDBF679F

Q34766146-6F2CBE50-E524-4C8C-ABEE-A1189F9B2E6A

Q34766146-A3D6BF00-FFD4-410E-8B1C-FC1616C36970

Q34766146-A95FB80F-2B19-4FE3-8A74-53FB4D3F0FF6

Q34766146-ABEE6A04-FA1F-45B2-B61E-192DC113D9DB

Q34766146-E8AA5D2F-066C-4612-ABAD-D5046D68CC75

P2860

Q34766146-0944DE2A-42CD-4BA7-A6DD-41B4502E6BED

Q34766146-1BAF461C-D50D-4DA2-8AC0-1E069F122022

Q34766146-2E2BF9F8-202F-4A57-AE95-FFEB801EDB11

Q34766146-2ED51B37-89F7-442F-9A8D-C3E8B087E2F2

Q34766146-3F92798D-F215-4543-A233-9EE93992679E

Q34766146-4380FB95-6F6E-4669-87F0-CF2B13A7BEFC

Q34766146-53664767-B96F-41F7-AE91-A33033D2371D

Q34766146-60443C83-CAEF-4E36-A3F4-6DDFABF756CC

Q34766146-6AEB3BF4-74F1-488B-8315-AC86DA710F7F

Q34766146-758D5D6A-DC22-4315-87CA-66BE1BF03BD6

P304

Q34766146-81079621-2762-49E2-9A45-3A756C32382D

P31

Q34766146-7EF99B07-D36E-4904-8F99-DF77731A7E56

P356

Q34766146-1892BD36-FF72-4733-816C-F7A78B346A0E

P407

Q34766146-9E017158-164A-4EC6-9E18-2AEFA09DF845

P433

Q34766146-8858BEB2-9420-4A65-840A-8A5D076708D1

P478

Q34766146-A5D06B42-3E27-4DF9-A973-85346EC6BBAA

P50

Q34766146-59BD7C8F-8A6A-45C1-A361-7F8C66D485C5

P577

Q34766146-C099B310-3AA4-4708-84AF-9A9EBA97C4E5

P698

Q34766146-802633C5-9798-445A-9C25-A7D5FF561428

P932

Q34766146-D8432E3F-6A01-4A7C-AD60-1B64C0A1D078

P356

CIRCULATIONAHA.113.006588

P1433

P1476

Rethinking composite end points in clinical trials: insights from patients and trialists.

@en

P2093

Brady B Lonergan

http://www.w3.org/2001/XMLSchema#string

David J Cohen

http://www.w3.org/2001/XMLSchema#string

Emily Bamberger

http://www.w3.org/2001/XMLSchema#string

Joshua M Stolker

http://www.w3.org/2001/XMLSchema#string

Kaushik K Jain

http://www.w3.org/2001/XMLSchema#string

Paul S Chan

http://www.w3.org/2001/XMLSchema#string

Philip G Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

Univariate statistical analysis of environmental (compositional) data: problems and possibilities.

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

Some old and some new statistical tools for outcomes research

The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.

Weighting composite endpoints in clinical trials: essential evidence for the heart team.

P304

1254-1261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.113.006588

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P50

John A. Spertus

P577

2014-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25200210

http://www.w3.org/2001/XMLSchema#string

P932

4275445

http://www.w3.org/2001/XMLSchema#string